Dealing with high-risk AL Amyloidosis patients: a single hematologic Center Experience.

Immunoglobulin light chain (AL) amyloidosis is a disease hematological in nature that requires thoughtfully selected hematological therapies. However, the main clinical manifestations very rarely involve the hematopoietic system and are so subtle and deceptive which require to be managed by a few experienced centers. The heart and kidney are the two most frequently affected organs, and the outcome is heavily related to the degree of heart involvement 1. The Revised (2012) Mayo Clinic staging system identifies patients at stage I, II, III, and IV with median overall survival (OS) of 94.1, 40.3, 14, and 5.8 months, respectively 2.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 28, 2021 Category: Hematology Authors: Marcello Riva, Tamara Berno, Alberto Cipriani, Sara Altinier, Marny Fedrigo, Franco Noventa, Fausto Adami Source Type: research